Omvoh meets primary endpoint in paediatric ulcerative colitis – Eli Lilly
Eli Lilly and Company announced positive late-breaking one-year results from the Phase 3 SHINE-2 study of Omvoh (mirikizumab-mrkz) in pediatric patients ages 6 to 17 with moderately to… read more.
